New antibody drug shows promise for vitiligo in early trial
NCT ID NCT04338581
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2a trial tested an experimental drug called AMG 714 in 60 adults with vitiligo, a condition that causes white patches on the skin. The drug works by blocking a protein called IL-15, which may play a role in the disease. Participants received either AMG 714 or a placebo, and some also received light therapy if their skin didn't improve enough. The main goal was to see if the drug could reduce facial vitiligo by at least 35% after 24 weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
AMG 714 (an antibody that blocks IL-15)
What this could lead to
If it works, this could point toward a new treatment option for vitiligo that helps reduce white patches on the skin.
What could go wrong
This is a small, early-phase trial with only 60 participants. The drug may not work better than placebo, and side effects are possible. Results may not apply to everyone with vitiligo.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for VITILIGO are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Henry Ford Health System
Detroit, Michigan, 48202, United States
-
Northwell Health
Lake Success, New York, 11042, United States
-
Tufts Medical Center: Department of Dermatology
Boston, Massachusetts, 02111, United States
-
University of California Davis Health System: Department of Dermatology
Sacramento, California, 95816, United States
-
University of California, Irvine: Department of Dermatology
Irvine, California, 92697, United States
-
University of Massachusetts Medical School
Worcester, Massachusetts, 01605, United States
-
Yale University School of Medicine: Department of Dermatology
New Haven, Connecticut, 06520, United States